Suven Pharmaceuticals Ltd. (IN:COHANCE)
:COHANCE
Top Page
Suven Pharmaceuticals Ltd.
(COHANCE)
Select Model
Select Model
Rating:56Neutral
Price Target:
₹291.00
▼(-67.34% Downside)
Action:ReiteratedDate:02/14/26
Financial strength is the main positive (growth and a solid, low-debt balance sheet), but the score is pulled down by very weak technicals (sharp downtrend and negative momentum) and a demanding valuation (high P/E with no dividend yield provided).
Positive Factors
Robust revenue growth
Near-100% reported revenue growth indicates the company is successfully scaling CDMO programs and winning business. Durable top-line expansion improves fixed-cost absorption, funds reinvestment into capacity and R&D, and strengthens bargaining power with regulator-focused customers over the medium term.
Negative Factors
EPS contraction / declining net income
A large negative EPS growth rate signals margin pressure or one-off hits that reduce earnings power. Sustained EPS contraction can limit internal funding for expansion, lower earnings resilience to project delays, and may reflect operational or pricing challenges that impair long-term profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Robust revenue growth
Near-100% reported revenue growth indicates the company is successfully scaling CDMO programs and winning business. Durable top-line expansion improves fixed-cost absorption, funds reinvestment into capacity and R&D, and strengthens bargaining power with regulator-focused customers over the medium term.
Read all positive factors
Suven Pharmaceuticals Ltd. (COHANCE) vs. iShares MSCI India ETF (INDA)
Market Cap
₹118.35B
Dividend YieldN/A
Average Volume (3M)116.47K
Price to Earnings (P/E)92.3
Beta (1Y)0.55
Revenue Growth88.74%
EPS Growth-14.95%
CountryIN
Employees1,193
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)1.05
Shares Outstanding382,567,140
10 Day Avg. Volume24,499
30 Day Avg. Volume116,469
Financial Highlights & Ratios
PEG Ratio-9.48
Price to Book (P/B)16.23
Price to Sales (P/S)23.00
P/FCF Ratio207.95
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)8.54
Revenue Forecast (FY)₹25.96B
Suven Pharmaceuticals Ltd. Business Overview & Revenue Model
Company Description
Cohance Lifesciences Limited is a Hyderabad-based pharmaceutical company specializing in contract development and manufacturing (CDMO) services, active pharmaceutical ingredients (APIs), and specialty chemicals. The company was formerly known as S...
How the Company Makes Money
Suven Pharmaceuticals primarily makes money through contract services (CDMO/CRAMS), where it is paid by other pharmaceutical and biotech companies to develop processes and manufacture small-molecule APIs and intermediates. Revenue is generated via...
Suven Pharmaceuticals Ltd. Financial Statement Overview
Summary
Income Statement
75
Positive
Balance Sheet
80
Positive
Cash Flow
70
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 18.14B | 11.98B | 10.51B | 13.40B | 13.20B | 10.10B |
| Gross Profit | 12.65B | 8.22B | 6.80B | 7.52B | 7.46B | 5.73B |
| EBITDA | 4.30B | 4.06B | 4.09B | 5.73B | 5.79B | 4.41B |
| Net Income | 2.48B | 2.68B | 3.00B | 4.11B | 4.54B | 3.62B |
Balance Sheet | ||||||
| Total Assets | 55.68B | 30.32B | 22.54B | 19.66B | 18.30B | 14.74B |
| Cash, Cash Equivalents and Short-Term Investments | 4.03B | 2.90B | 8.21B | 4.84B | 5.26B | 1.88B |
| Total Debt | 4.51B | 2.79B | 649.96M | 703.41M | 971.27M | 1.43B |
| Total Liabilities | 16.44B | 11.91B | 2.03B | 2.31B | 3.02B | 2.94B |
| Stockholders Equity | 37.88B | 16.97B | 20.51B | 17.35B | 15.27B | 11.81B |
Cash Flow | ||||||
| Free Cash Flow | 1.71B | 1.32B | 3.07B | 1.65B | 2.55B | 2.73B |
| Operating Cash Flow | 2.61B | 2.88B | 3.58B | 4.51B | 3.30B | 3.83B |
| Investing Cash Flow | -1.94B | -2.55B | -3.62B | -1.95B | -1.36B | -3.11B |
| Financing Cash Flow | -828.50M | 33.20M | -138.02M | -2.36B | -1.56B | -765.53M |
Suven Pharmaceuticals Ltd. Technical Analysis
Neutral
891.10
Price Trends
321.94
Negative
428.18
Negative
679.88
Negative
Market Momentum
-5.31
Negative
49.72
Neutral
46.54
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:COHANCE, the sentiment is Neutral. The current price of 891.1 is above the 20-day moving average (MA) of 299.69, above the 50-day MA of 321.94, and above the 200-day MA of 679.88, indicating a neutral trend. The MACD of -5.31 indicates Negative momentum. The RSI at 49.72 is Neutral, neither overbought nor oversold. The STOCH value of 46.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:COHANCE.
Suven Pharmaceuticals Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | ₹366.69B | 27.58 | ― | 0.28% | 9.66% | 25.79% | |
72 Outperform | ₹338.54B | 31.59 | ― | 1.04% | 10.74% | 11.91% | |
66 Neutral | ₹584.58B | 59.42 | ― | 0.15% | 25.83% | 421.20% | |
63 Neutral | ₹566.77B | 91.56 | ― | 0.12% | 10.62% | -66.88% | |
56 Neutral | ₹118.35B | 92.29 | ― | ― | 88.74% | -14.95% | |
53 Neutral | ₹613.60B | 35.61 | ― | 0.24% | 30.27% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:COHANCE
Suven Pharmaceuticals Ltd.
309.35
-742.30
-70.58%
IN:AJANTPHARM
Ajanta Pharma Limited
2,709.75
269.21
11.03%
IN:BIOCON
Biocon Limited
350.00
45.21
14.83%
IN:GLENMARK
Glenmark Pharmaceuticals Limited
2,174.35
800.87
58.31%
IN:IPCALAB
IPCA Laboratories Limited
1,445.60
151.15
11.68%
IN:LAURUSLABS
Laurus Labs Ltd.
1,082.85
520.68
92.62%
Suven Pharmaceuticals Ltd. Corporate Events
Cohance Lifesciences to Engage Investors at IIFL and Kotak Conferences in February 2026
Feb 20, 2026
Cohance Lifesciences Limited has announced that its management will participate in the IIFL Entrepreneurial India Conference in Mumbai on February 25, 2026, and the Kotak Chasing Growth Conference on February 26, 2026, engaging in both group and o...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.